Zephyr AI
Harnesses real-world data for precision medicine optimization.. [Contact for Pricing]
Last verified:
What is Zephyr AI?
Zephyr AI is a precision-medicine platform that applies multi‑modal AI to large-scale real‑world data to generate actionable insights across the therapeutic lifecycle. The platform ingests and harmonizes EHR, claims, genomics, pathology, and longitudinal datasets (including deeply profiled oncology cohorts) to enable discovery, biomarker development, and clinical translation. Zephyr offers models and datasets designed to de-risk drug development, optimize patient selection, and power AI‑enabled companion diagnostics that can be fine‑tuned to partner assays and assets. Its products include tools for reconstructing expression from DNA-based tests, predictive models for treatment response (including immune checkpoint inhibitors), and linked patient cohorts for translational research and health‑economics decisioning.
Zephyr AI pricing
Pricing model: Freemium
Zephyr AI presents its platform and partnership model as custom, enterprise offerings rather than fixed public plans. The website does not list a free tier, trial, or fixed plan prices; instead, commercial access and scope are configured through partnership engagements that determine deliverables, timelines, and pricing.
Zephyr AI pros
- Combines multi‑modal AI with enterprise‑scale real‑world data
- Access to 90M+ patients and 1M+ oncology patients with NGS
- Interpretable models built for discovery, validation, and deployment
- Prebuilt oncology cohorts with matched exome, transcriptome, and pathology
- Ability to predict response to small molecules and immunotherapies
- Reconstructs mRNA expression from DNA LDTs with high concordance
- Fine‑tunable AI-CDx workflows co‑developed with biopharma partners
- Platform designed to integrate directly into R&D and clinical workflows
- Can generate fit‑for‑purpose comparator arms for trials and HEOR
- Supports longitudinal model training on linked clinical data
- Scales from proof‑of‑concept pilots to clinical and commercial applications
- Secure, compliant infrastructure built for speed and enterprise scale
- Generates new molecular data to support regulatory and validation programs
- Designed to reduce development risk and accelerate clinical translation
- Offers tailored models enriched with biological context from diverse datasets
Zephyr AI cons
- No public self‑serve pricing or transparent tier structure on site
- Appears focused on enterprise and biopharma partnerships rather than small labs
- No clear public API documentation linked for developer integration
- No visible free tier or trial availability listed on the website
- Deliverables and onboarding timelines appear custom, not standardized
- Potential data‑access constraints for partners without large datasets
- Technical integration may require significant partner IT and regulatory effort
- Primary focus on oncology may limit immediate utility for other therapeutic areas
Frequently asked questions about Zephyr AI
What types of data does Zephyr ingest and analyze?
Zephyr ingests multi‑modal real‑world data including EHR, claims, genomics, pathology, and linked longitudinal datasets, and it maintains deeply profiled oncology cohorts used for model training and translational research.
Can Zephyr predict response to immunotherapies?
Yes — Zephyr publishes models that predict response to immune checkpoint inhibitors and small molecules using clinically available inputs, with validation performed in real‑world cohorts.
Does Zephyr provide prebuilt patient cohorts?
Yes — the platform includes matched clinical, exome, transcriptome, and digital pathology cohorts (Aster Avatar) with longitudinal updates designed for translational research and biomarker discovery.
Can Zephyr be integrated into existing R&D workflows?
Yes — the platform is built to integrate directly into partner R&D and clinical workflows, allowing models and insights to be deployed without requiring partners to build new assays.
Does Zephyr offer companion diagnostic development?
Yes — Zephyr co‑develops fine‑tuned companion diagnostics (AI‑CDx) with biopharma and diagnostics partners, adapting models to partner assays and available preclinical or clinical data.
How fast can Zephyr launch pilots?
Zephyr states it can launch proof‑of‑concept pilots in weeks and scale those pilots to clinical and commercial applications without re‑engineering core systems, though exact timelines depend on the partner scope and data access.
Is there a public API or developer portal?
The public website does not display a documented public API or developer portal; integrations and technical access appear to be managed through enterprise partnerships and onboarding.
What regulatory or compliance measures are in place?
Zephyr describes its infrastructure as secure and compliant for enterprise use, implying attention to regulatory needs for clinical and commercial deployment, with specific compliance arrangements handled as part of partner engagements.
Does Zephyr offer pricing or trial plans on the website?
No — the website presents Zephyr as a custom, partnership‑driven service and does not list public pricing, free tiers, or trial options; commercial terms are determined during partnership discussions.
Which therapeutic areas does Zephyr primarily support?
Zephyr emphasizes oncology and chronic disease research, with deep investments in oncology cohorts and models; other therapeutic areas may be supported but oncology is the primary focus showcased on the site.